Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dorzolamide Hydrochloride

FDA-approved product (solution/drops, ophthalmic), marketed as Dorzolamide Hydrochloride, Trusopt.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dorzolamide Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis86.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Dorzolamide Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dorzolamide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH

    NCT07690397 · start 2026-06-10

    Registered record
    Registry ID
    NCT07690397
    Conditions
    Primary Open-Angle Glaucoma (POAG); Ocular Hypertension
    Interventions
    Preservative-free dorzolamide-timolol-brimonidine combination; Preservative dorzolamide-timolol-brimonidine combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2026-06-10
    Completion
    2027-09-01
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open-Angle Glaucoma (POAG); Ocular Hypertension
    InterventionPreservative-free dorzolamide-timolol-brimonidine combination; Preservative dorzolamide-timolol-brimonidine combination
    PhasePhase 4
    Registry statusActive not recruiting

  • Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma

    NCT07617532 · start 2026-06

    Registered record
    Registry ID
    NCT07617532
    Conditions
    Ocular Hypertension; Primary Open Angle Glaucoma
    Interventions
    Product DNN.31.19.026; COSOPT®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-06
    Completion
    2028-03
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Primary Open Angle Glaucoma
    InterventionProduct DNN.31.19.026; COSOPT®
    PhasePhase 3
    Registry statusNot yet recruiting

  • Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

    NCT07074782 · start 2026-05

    Registered record
    Registry ID
    NCT07074782
    Conditions
    Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2026-06
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

    NCT07335211 · start 2026-01

    Registered record
    Registry ID
    NCT07335211
    Conditions
    Primary Open Angle Glaucoma (POAG); Ocular Hypertension
    Interventions
    HUC3-637; HUC3-637-R
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01
    Completion
    2027-12
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma (POAG); Ocular Hypertension
    InterventionHUC3-637; HUC3-637-R
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

    NCT06883123 · start 2025-05-14

    Registered record
    Registry ID
    NCT06883123
    Conditions
    Open Angle Glaucoma
    Interventions
    Simbrinza 0.2%-1% Ophthalmic Suspension; Rocklatan 0.02%-0.005% Ophthalmic Solution; Cosopt PF 2%-0.5% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-14
    Completion
    2026-04-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma
    InterventionSimbrinza 0.2%-1% Ophthalmic Suspension; Rocklatan 0.02%-0.005% Ophthalmic Solution; Cosopt PF 2%-0.5% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution
    PhasePhase 4
    Registry statusRecruiting

  • How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

    NCT06369077 · start 2024-04-22

    Registered record
    Registry ID
    NCT06369077
    Conditions
    Glaucoma, Open-Angle; Glaucoma; Drugs
    Interventions
    dorzolamide/timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2024-04-22
    Completion
    2024-07-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Glaucoma; Drugs
    Interventiondorzolamide/timolol
    PhasePhase 4
    Registry statusTerminated

  • A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

    NCT06177678 · start 2024-02

    Registered record
    Registry ID
    NCT06177678
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    TFC-003; COSOPT ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-02
    Completion
    2024-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionTFC-003; COSOPT ophthalmic solution
    PhasePhase 2
    Registry statusUnknown

  • Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

    NCT05857267 · start 2023-03-07

    Registered record
    Registry ID
    NCT05857267
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Dorzolamide / Timolol Ophthalmic Solution; dorzolamide/timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-03-07
    Completion
    2024-11-04
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionDorzolamide / Timolol Ophthalmic Solution; dorzolamide/timolol
    PhasePhase 4
    Registry statusCompleted

  • Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

    NCT04702789 · start 2021-10-19

    Registered record
    Registry ID
    NCT04702789
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Dorzolamide-timolol-brimonidine and latanoprost; Dorzolamide-timolol and latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2021-10-19
    Completion
    2023-11-23
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionDorzolamide-timolol-brimonidine and latanoprost; Dorzolamide-timolol and latanoprost
    PhasePhase 4
    Registry statusTerminated

  • Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema

    NCT05083689 · start 2021-10-06

    Registered record
    Registry ID
    NCT05083689
    Conditions
    Diabetic Macular Edema
    Interventions
    Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide; Injections of 1.25 mg of intravitreal bevacizumab with artificial tears
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-10-06
    Completion
    2022-04
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Macular Edema
    InterventionInjections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide; Injections of 1.25 mg of intravitreal bevacizumab with artificial tears
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

    NCT04676126 · start 2021-05

    Registered record
    Registry ID
    NCT04676126
    Conditions
    Glaucoma; Glaucoma Eye; Glaucoma, Open-Angle
    Interventions
    Lumega-Z; Dorzolamide Hcl 2% Oph Soln; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-05
    Completion
    2022-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Glaucoma Eye; Glaucoma, Open-Angle
    InterventionLumega-Z; Dorzolamide Hcl 2% Oph Soln; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

    NCT04448223 · start 2020-06-11

    Registered record
    Registry ID
    NCT04448223
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    CKD-351; Latanoprost+Dorzolmamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-06-11
    Completion
    2022-12-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionCKD-351; Latanoprost+Dorzolmamide
    PhasePhase 2
    Registry statusUnknown

  • Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®

    NCT03966365 · start 2019-05-02

    Registered record
    Registry ID
    NCT03966365
    Conditions
    Glaucoma
    Interventions
    PRO-122; Krytantek Ofteno®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-05-02
    Completion
    2019-08-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionPRO-122; Krytantek Ofteno®
    PhasePhase 1
    Registry statusCompleted

  • Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

    NCT02852057 · start 2018-01-18

    Registered record
    Registry ID
    NCT02852057
    Conditions
    Glaucoma
    Interventions
    timolol maleate and dorzolamide hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-18
    Completion
    2021-08-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Interventiontimolol maleate and dorzolamide hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

    NCT03193333 · start 2017-11-06

    Registered record
    Registry ID
    NCT03193333
    Conditions
    Primary Open-angle Glaucoma
    Interventions
    PRO-122; Timolol eye drops; Dorzolamide-Timolol Ophthalmic; Brimonidine Ophthalmic Solution; Placebo1; Placebo 2; Krytantek
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-11-06
    Completion
    2024-10-30
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open-angle Glaucoma
    InterventionPRO-122; Timolol eye drops; Dorzolamide-Timolol Ophthalmic; Brimonidine Ophthalmic Solution +3 more
    PhasePhase 3
    Registry statusTerminated